Piper Jaffray Starts Celyad SA (CYAD) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
UPDATE: UBS Starts Celyad SA (CYAD) at Buy
July 14, 2015 8:22 AM EDT(Updated - July 14, 2015 8:43 AM EDT)
UBS initiates coverage on Celyad SA (NASDAQ: CYAD) with a Buy rating and a price target of $82.00.
Analyst Andrew Peters commented, "We are initiating coverage on Celyad SA with a Buy rating and $82 price target following an extensive analysis of the phase-3 C-Cure program in heart failure as well as the NK-based CAR-T technology currently in phase-1 trials. We believe initial proofof-concept data from... More
